Tirzepatide in the UK: Mounjaro Availability, Cost & Where to Get It (2026)

Overview

Tirzepatide is the active ingredient in Mounjaro, developed by Eli Lilly and Company. It is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist — meaning it activates two separate hormonal pathways involved in appetite regulation, insulin secretion, and energy metabolism. This dual mechanism differentiates it from semaglutide (Ozempic, Wegovy), which targets only GLP-1 receptors. In the UK, tirzepatide was approved by the MHRA (Medicines and Healthcare products Regulatory Agency) in November 2023 under the brand name Mounjaro, initially for the management of type 2 diabetes (T2D) and subsequently for chronic weight management. NICE Technology Appraisal TA1026 (2023) recommends Mounjaro for obesity treatment through NHS Tier 3 specialist services. This guide covers tirzepatide's availability in the UK, how to access it through NHS and private routes, what it costs, the dose titration schedule used in UK clinics, and how it compares to semaglutide in the UK market context.

MHRA Approval and UK Licensing

Tirzepatide (Mounjaro) received MHRA approval in the UK in 2023 following an extensive review of the SURPASS clinical trial programme (for T2D) and the SURMOUNT programme (for obesity). The MHRA assessed the drug's safety, efficacy, and quality, and concluded that the benefits outweigh the risks for the approved indications. Monjaro in the UK is licensed in multiple dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, each available as a once-weekly subcutaneous auto-injector pen. The drug is manufactured and supplied by Eli Lilly UK Ltd. The UK Summary of Product Characteristics (SmPC) provides detailed prescribing information and contraindications for UK healthcare professionals.

• MHRA approved tirzepatide (Mounjaro) in November 2023
• Licensed for type 2 diabetes (T2D) management and chronic weight management
• Available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg dose strengths
• Once-weekly subcutaneous auto-injector pen
• Manufactured and distributed by Eli Lilly UK Ltd

NHS Access: Tier 3 and NICE TA1026

NHS access to tirzepatide (Mounjaro) for obesity management is governed by NICE Technology Appraisal TA1026, published in 2023. This restricts NHS prescribing to specialist Tier 3 weight management services, which are multidisciplinary clinical teams offering intensive weight management support. Patients must meet the BMI criteria (≥35, or ≥30 for high-risk ethnic groups) and have at least one obesity-related comorbidity. For type 2 diabetes, tirzepatide may be prescribed by diabetes care teams under separate NICE guidance (TA924), providing an additional NHS access route for T2D patients. This pathway is distinct from the obesity pathway and is managed by endocrinology or primary care diabetology teams rather than weight management services.

• Obesity pathway: NICE TA1026 — must be in Tier 3 specialist service
• BMI ≥35 (or ≥30 for high-risk ethnic groups) + ≥1 comorbidity required
• T2D pathway: NICE TA924 — prescribed by diabetes teams without Tier 3 requirement
• NHS cost: standard prescription charge (~£9.90) or free if exempt
• Both pathways involve regular clinical monitoring and reassessment

Private Tirzepatide in the UK: Cost and Providers

For patients who do not qualify for NHS Mounjaro, cannot face long NHS waiting times, or want to start treatment immediately, private prescriptions are available across the UK. Private tirzepatide (Mounjaro) typically costs between £150 and £250 per month, depending on the dose. As of 2026, providers offering private Mounjaro prescriptions in the UK include Boots Online Doctor, Juniper Health, Manual, Voy (Vitality), and various private obesity clinics and GP practices. Most require an initial online or in-person consultation to assess medical suitability before prescribing. Follow-up consultations are typically required every 1–3 months. The drug is dispensed and delivered by registered UK pharmacies.

• Private Mounjaro cost: £150–250/month depending on dose
• 2.5 mg/5 mg starter doses: ~£150–175/month
• 10 mg/15 mg maintenance doses: ~£200–250/month
• Providers: Boots Online Doctor, Juniper, Manual, Voy, private clinics
• Initial consultation: £50–150 (varies by provider)
• Delivery by registered UK pharmacy — same drug as NHS version

Tirzepatide Dose Titration: UK Clinical Practice

UK prescribers follow the MHRA-approved titration schedule for Mounjaro, which involves starting at a low dose and gradually increasing every 4 weeks to minimise gastrointestinal side effects. The standard UK titration schedule mirrors the clinical trial protocol: Weeks 1–4: 2.5 mg/week. Weeks 5–8: 5 mg/week. Weeks 9–12: 7.5 mg/week. Weeks 13–16: 10 mg/week. Weeks 17–20: 12.5 mg/week. Weeks 21+: 15 mg/week (maximum dose). In UK Tier 3 services and private clinics, prescribers often slow down titration if a patient experiences significant nausea or GI symptoms, remaining at a given dose for 8 weeks instead of 4 before escalating. The minimum effective maintenance dose for meaningful weight loss is generally considered to be 5 mg, with 10–15 mg producing the greatest results. UK GPs and nurses in private services are trained in the titration protocol before prescribing.

• Weeks 1–4: 2.5 mg/week (starter dose)
• Weeks 5–8: 5 mg/week
• Weeks 9–12: 7.5 mg/week
• Weeks 13–16: 10 mg/week
• Weeks 17–20: 12.5 mg/week
• Weeks 21+: 15 mg/week (maximum)
• UK practice: slow down titration if GI side effects are significant

Tirzepatide vs Semaglutide: UK Prescribing Context

Both tirzepatide (Mounjaro) and semaglutide (Wegovy/Ozempic) are available in the UK through NHS and private routes. When choosing between them, UK Tier 3 clinicians consider individual patient factors including medical history, previous treatment response, and patient preference. Clinical trial data (SURMOUNT-1 for tirzepatide vs STEP 1 for semaglutide) suggests tirzepatide produces greater average weight loss at maximum doses — approximately 22.5% versus 14.9% — though direct head-to-head UK trials are not available. Both drugs are GLP-1 receptor agonists, but tirzepatide's additional GIP activity may contribute to greater efficacy for some patients. From a cost perspective, both are priced similarly in the UK private market (£150–250/month).

• Tirzepatide (SURMOUNT-1 max dose): ~22.5% mean weight loss at 72 weeks
• Semaglutide (STEP 1 max dose): ~14.9% mean weight loss at 68 weeks
• No direct head-to-head UK trials; cross-trial comparisons have limitations
• Both available through NHS Tier 3 and private routes
• Similar cost in UK private market: £150–250/month
• Tirzepatide: dual GIP + GLP-1; Semaglutide: GLP-1 only

Where to Get Tirzepatide in the UK

UK residents have several options for accessing tirzepatide (Mounjaro). The NHS route requires referral from a GP to a Tier 3 service (for obesity) or through a diabetes team (for T2D). Waiting times for Tier 3 services vary from weeks to over a year depending on your ICB. NHS access is free (standard prescription charge applies). For faster private access, online prescribing platforms offer nationwide UK delivery. Juniper, Manual, Voy, and Boots Online Doctor are among the most widely used. Private clinics in cities including London, Manchester, Birmingham, and Edinburgh also offer tirzepatide weight loss programmes with face-to-face support. Eli Lilly operates a UK patient support programme (the Mounjaro Care Programme) that provides injection training, dietary advice, and nurse support to patients on the drug.

References

1. NICE Technology Appraisal TA1026: Tirzepatide for Managing Overweight and Obesity (2023)
2. NICE Technology Appraisal TA924: Tirzepatide for Type 2 Diabetes (2023)
3. MHRA: Mounjaro (Tirzepatide) UK Product Licence and Public Assessment Report (2023)
4. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) (2022) — PubMed